



FOR IMMEDIATE RELEASE

**Dr. Reid Jilek and Mr. Donald Steinberg
appointed to Arris Holdings Inc.'s wholly owned U.S. Subsidiary Global Hemp Group, Inc.**

Surrey, British Columbia, Canada / December 18, 2013 / CNSX: AAF / Frankfurt: ANI / Arris Holdings Inc. ("Arris" or the "Company") is pleased to announce the appointment of Dr. Reid Jilek and Donald Steinberg to the board of directors of its U.S. subsidiary, Global Hemp Group, Inc.

This newly formed Arris subsidiary will focus on opportunities unfolding in the emerging hemp industry in the United States. Arris management expects double-digit growth in this sector for the next 3 to 5 years. Arris and Global Hemp Group are positioning to capitalize on this anticipated rapid growth and the business opportunities that are developing.

"I look forward to working with the Global Hemp Group team, helping guide the Company as it moves ahead with its ambitious plans into this emerging industry," said Mr. Steinberg

In the 1980's Mr. Steinberg developed stock option programs that led to management of floor traders on multiple option exchanges and provided him with invaluable insight into the public markets and public company management. Donald is a serial entrepreneur and has launched multiple successful companies in his career. Notably, Mr. Steinberg was the founder of the first publically traded medical marijuana company on the U.S. stock market, Medical Marijuana, Inc., which provides him with unique insight and industry experience that will be invaluable in the execution of the Global Hemp Group, Inc. business plan. Mr. Steinberg also has extensive sales and marketing experience and has launched and managed several successful direct sales platforms and will apply that knowledge and expertise to the Global Hemp Group sales and marketing efforts as well as oversee company wide operations.

Dr. Reid Jilek says, "I am very excited to be joining Global Hemp Group and to utilize my network of international contacts to tap the brain power and technologies that are required for the evolution of this new and exciting sustainable industry".

Dr. Jilek has advanced degrees in the medical, life science and engineering disciplines. He was both a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer-reviewed journals. After completing his National Library of Medicine Post-Doctoral developing computer and mathematical models for Malaria, he decided to utilize his medical and scientific background in a business development capacity by acting as a VP of Business Development for private and public companies and a research institute. He was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990, in the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Moscow, Israel and Germany. He has also served as the CEO of four companies and is now a member of the Advisory Board for the Hemp Industrial Innovation Institute. Dr. Jilek's extensive network of business, political, environmental and social leaders in the world provides Global Hemp Group with a unique source of knowledge and expertise that is invaluable to the company.

On behalf of the board

Charles Larsen
CEO

For additional information please call 1-604-592-6881 or 1-877-469-HEMP (4367).

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.